{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:01:45Z","timestamp":1788307305788,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-25-1-0262"],"award-info":[{"award-number":["HT9425-25-1-0262"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-23-1-0223"],"award-info":[{"award-number":["HT9425-23-1-0223"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"crossref","award":["CRDG-2024-3-1550"],"award-info":[{"award-number":["CRDG-2024-3-1550"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastasis is the leading cause of cancer-related mortality. In ovarian cancer, dissemination within the peritoneal cavity is the primary driver of patient death, underscoring a critical need to define the molecular mechanisms that initiate metastatic seeding and remodel the peritoneal microenvironment. Stem-like tumor cell programs are increasingly recognized as central to metastatic competence, yet the regulators linking tumor stemness to microenvironmental reprogramming remain poorly defined. Doublecortin-like kinase 1 (DCLK1), a serine\/threonine kinase associated with tumor stemness, has been implicated in cancer progression, but its role in ovarian cancer metastasis is not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed genetic loss-of-function approaches to investigate the role of DCLK1 in ovarian cancer metastasis using in vivo intraperitoneal dissemination models. Metastatic burden and overall survival were assessed following DCLK1 depletion. DCLK1 expression was analyzed across patient-derived ascites cultures established from primary and recurrent ovarian cancer patients and correlated with markers of metastasis-initiating cells. Functional assays were used to assess tumor cell adhesion, mesothelial clearance, stemness features and mesothelial-to-mesenchymal transition. Targeted transcriptomic and secretome analyses identified DCLK1-regulated cytokine programs. Paracrine signaling to mesothelial cells was evaluated using pharmacologic inhibition of IL-6 receptor and downstream JAK\u2013STAT signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genetic loss of DCLK1 significantly reduced intraperitoneal metastatic burden and prolonged overall survival in vivo. DCLK1 expression correlated strongly with established markers of stem-like, metastasis-initiating tumor cells across the patient-derived ascites cultures. Mechanistically, DCLK1 promoted early metastatic colonization by enhancing tumor cell adhesion, mesothelial clearance, and mesothelial-to-mesenchymal transition. Transcriptomic and secretome profiling identified interleukin-6 (IL-6) as a key downstream effector of DCLK1, with DCLK1 depletion leading to a marked reduction in IL-6 expression and secretion. Tumor-derived IL-6 activated JAK\u2013STAT signaling in mesothelial cells, promoting mesothelial migration and a permissive metastatic niche; these effects were reversed by pharmacologic blockade of IL-6 receptor signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings position DCLK1 as a central molecular mediator linking tumor-intrinsic stemness to microenvironmental reprogramming that primes the peritoneal niche for metastatic progression. Targeting DCLK1 or downstream IL-6\/JAK\u2013STAT signaling may therefore offer a rational strategy to disrupt metastatic dissemination in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03739-x","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:36:33Z","timestamp":1779950193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DCLK1 regulates stemness and IL-6\/STAT3\u2013dependent metastatic niche formation in chemoresistant ovarian cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Samrita","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugantha Priya","family":"Elayapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Hladik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameera","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitreyee","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F.","family":"Mortan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney W.","family":"Houchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany N.","family":"Hannafon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"3739_CR1","doi-asserted-by":"publisher","first-page":"1539024","DOI":"10.3389\/fmed.2025.1539024","volume":"12","author":"M Deng","year":"2025","unstructured":"Deng M, Yang R, Jiang J, Zhang J, He J, Miao J. The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer. Front Med (Lausanne). 2025;12:1539024.","journal-title":"Front Med (Lausanne)"},{"key":"3739_CR2","doi-asserted-by":"publisher","first-page":"886533","DOI":"10.3389\/fendo.2022.886533","volume":"13","author":"SJ Ritch","year":"2022","unstructured":"Ritch SJ, Telleria CM. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination. Front Endocrinol (Lausanne). 2022;13:886533.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3739_CR3","doi-asserted-by":"crossref","unstructured":"Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT et al. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest. 2021;131(16):e146186.","DOI":"10.1172\/JCI146186"},{"key":"3739_CR4","doi-asserted-by":"crossref","unstructured":"Drapela S, Gomes AP. Metabolic requirements of the metastatic cascade. Curr Opin Syst Biol. 2021;28:100381.","DOI":"10.1016\/j.coisb.2021.100381"},{"issue":"2","key":"3739_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177\u201385.","journal-title":"Cancer Lett"},{"issue":"8","key":"3739_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1101\/gad.277681.116","volume":"30","author":"T Celia-Terrassa","year":"2016","unstructured":"Celia-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30(8):892\u2013908.","journal-title":"Genes Dev"},{"key":"3739_CR7","doi-asserted-by":"crossref","unstructured":"Wang J, Ford JC, Mitra AK. Defining the Role of Metastasis-Initiating Cells in Promoting Carcinogenesis in Ovarian Cancer. Biology (Basel). 2023;12(12):1492.","DOI":"10.3390\/biology12121492"},{"issue":"5","key":"3739_CR8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.fertnstert.2016.09.005","volume":"106","author":"SE Mutsaers","year":"2016","unstructured":"Mutsaers SE, Prele CM, Pengelly S, Herrick SE. Mesothelial cells and peritoneal homeostasis. Fertil Steril. 2016;106(5):1018\u201324.","journal-title":"Fertil Steril"},{"key":"3739_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/1471-2407-14-288","volume":"14","author":"I Matte","year":"2014","unstructured":"Matte I, Lane D, Bachvarov D, Rancourt C, Piche A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer. 2014;14:288.","journal-title":"BMC Cancer"},{"key":"3739_CR10","doi-asserted-by":"crossref","unstructured":"Bilandzic M, Stenvers KL. Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time. J Vis Exp. 2014(87):51655.","DOI":"10.3791\/51655"},{"issue":"4","key":"3739_CR11","first-page":"2105","volume":"40","author":"A Shishido","year":"2018","unstructured":"Shishido A, Mori S, Yokoyama Y, Hamada Y, Minami K, Qian Y, et al. Mesothelial cells facilitate cancer stem\u2013like properties in spheroids of ovarian cancer cells. Oncol Rep. 2018;40(4):2105\u201314.","journal-title":"Oncol Rep"},{"key":"3739_CR12","doi-asserted-by":"publisher","first-page":"473134","DOI":"10.1155\/2014\/473134","volume":"2014","author":"M Lopez-Cabrera","year":"2014","unstructured":"Lopez-Cabrera M. Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis. Adv Med. 2014;2014:473134.","journal-title":"Adv Med"},{"key":"3739_CR13","doi-asserted-by":"publisher","first-page":"965730","DOI":"10.3389\/fmolb.2022.965730","volume":"9","author":"D Chhetri","year":"2022","unstructured":"Chhetri D, Vengadassalapathy S, Venkadassalapathy S, Balachandran V, Umapathy VR, Veeraraghavan VP, et al. Pleiotropic effects of DCLK1 in cancer and cancer stem cells. Front Mol Biosci. 2022;9:965730.","journal-title":"Front Mol Biosci"},{"issue":"7","key":"3739_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1158\/1535-7163.MCT-19-0776","volume":"19","author":"P Chandrakesan","year":"2020","unstructured":"Chandrakesan P, Panneerselvam J, May R, Weygant N, Qu D, Berry WR, et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Mol Cancer Ther. 2020;19(7):1539\u201349.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"3739_CR15","doi-asserted-by":"publisher","first-page":"9269","DOI":"10.18632\/oncotarget.2393","volume":"5","author":"P Chandrakesan","year":"2014","unstructured":"Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, et al. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014;5(19):9269\u201380.","journal-title":"Oncotarget"},{"key":"3739_CR16","doi-asserted-by":"crossref","unstructured":"Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers (Basel). 2020;12(12):3801.","DOI":"10.3390\/cancers12123801"},{"key":"3739_CR17","doi-asserted-by":"crossref","unstructured":"Nakagawa A, Von Alt KN, Mino-Kenudson M, Adams CE, Purschke B, Taniue K et al. De novo formation of tuft and goblet cells protects the intrapancreatic biliary duct system from inflammatory injury. FEBS J. 2026;293(7):2133\u201354.","DOI":"10.1111\/febs.70330"},{"issue":"4","key":"3739_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1440-1746.2011.06928.x","volume":"27","author":"KJ Vega","year":"2012","unstructured":"Vega KJ, May R, Sureban SM, Lightfoot SA, Qu D, Reed A, et al. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett\u2019s esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol. 2012;27(4):773\u201380.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"3739_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/CBM-210330","volume":"33","author":"E Kalantari","year":"2022","unstructured":"Kalantari E, Ghods R, Saeednejad Zanjani L, Rahimi M, Eini L, Razmi M, et al. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer. Cancer Biomark. 2022;33(3):277\u201389.","journal-title":"Cancer Biomark"},{"key":"3739_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers13225729","volume":"13","author":"L Ding","year":"2021","unstructured":"Ding L, Yang Y, Ge Y, Lu Q, Yan Z, Chen X, et al. Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity. Cancers (Basel). 2021;13:22.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3739_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12964-025-02400-y","volume":"23","author":"L Huang","year":"2025","unstructured":"Huang L, Li T, Huang X, Chen X, Ju Y, Xu L, et al. Tumor necrosis factor promotes doublecortin-like kinase 1 expression and cellular reprogramming in intestinal epithelial cells leading to neoplastic transformation. Cell Commun Signal. 2025;23(1):415.","journal-title":"Cell Commun Signal"},{"key":"3739_CR22","doi-asserted-by":"publisher","first-page":"216437","DOI":"10.1016\/j.canlet.2023.216437","volume":"578","author":"S Dogra","year":"2023","unstructured":"Dogra S, Elayapillai SP, Qu D, Pitts K, Filatenkov A, Houchen CW, et al. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer. Cancer Lett. 2023;578:216437.","journal-title":"Cancer Lett"},{"key":"3739_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers17193217","volume":"17","author":"PO Mirsky","year":"2025","unstructured":"Mirsky PO, Wagner PL, Mandic-Popov M, Donnenberg VS, Donnenberg AD. The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy. Cancers (Basel). 2025;17:19.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3739_CR24","doi-asserted-by":"publisher","first-page":"e6529","DOI":"10.1371\/journal.pone.0006529","volume":"4","author":"E Campeau","year":"2009","unstructured":"Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE. 2009;4(8):e6529.","journal-title":"PLoS ONE"},{"issue":"4","key":"3739_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41556-024-01372-4","volume":"26","author":"D Murthy","year":"2024","unstructured":"Murthy D, Attri KS, Shukla SK, Thakur R, Chaika NV, He C, et al. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Nat Cell Biol. 2024;26(4):613\u201327.","journal-title":"Nat Cell Biol"},{"issue":"13","key":"3739_CR26","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/j.celrep.2017.03.015","volume":"18","author":"C Francavilla","year":"2017","unstructured":"Francavilla C, Lupia M, Tsafou K, Villa A, Kowalczyk K, Rakownikow Jersie-Christensen R, et al. Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer. Cell Rep. 2017;18(13):3242\u201356.","journal-title":"Cell Rep"},{"issue":"3","key":"3739_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41418-021-00878-w","volume":"29","author":"T Velletri","year":"2022","unstructured":"Velletri T, Villa CE, Cilli D, Barzaghi B, Lo Riso P, Lupia M, et al. Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. Cell Death Differ. 2022;29(3):614\u201326.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3739_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-023-00495-5","volume":"8","author":"Y Fang","year":"2024","unstructured":"Fang Y, Xiao X, Wang J, Dasari S, Pepin D, Nephew KP, et al. Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling. NPJ Precis Oncol. 2024;8(1):7.","journal-title":"NPJ Precis Oncol"},{"issue":"1\u20132","key":"3739_CR29","first-page":"70","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1\u20132):70\u20138.","journal-title":"J Immunol Methods"},{"issue":"6","key":"3739_CR30","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/1541-7786.MCR-18-0989","volume":"17","author":"D Neelakantan","year":"2019","unstructured":"Neelakantan D, Dogra S, Devapatla B, Jaiprasart P, Mukashyaka MC, Janknecht R, et al. Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis. Mol Cancer Res. 2019;17(6):1378\u201390.","journal-title":"Mol Cancer Res"},{"issue":"Database issue","key":"3739_CR31","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gki005","volume":"33","author":"C von Mering","year":"2005","unstructured":"von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005;33(Database issue):D433\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3739_CR32","doi-asserted-by":"crossref","unstructured":"Davidowitz RA, Iwanicki MP, Brugge JS. In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. J Vis Exp. 2012(60):3888.","DOI":"10.3791\/3888"},{"issue":"2","key":"3739_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","volume":"1","author":"MP Iwanicki","year":"2011","unstructured":"Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(2):144\u201357.","journal-title":"Cancer Discov"},{"key":"3739_CR34","doi-asserted-by":"publisher","first-page":"762820","DOI":"10.3389\/fonc.2022.762820","volume":"12","author":"MW Caminear","year":"2022","unstructured":"Caminear MW, Harrington BS, Kamdar RD, Kruhlak MJ, Annunziata CM. Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells. Front Oncol. 2022;12:762820.","journal-title":"Front Oncol"},{"key":"3739_CR35","doi-asserted-by":"crossref","unstructured":"Burkhard KM, Semwal A, Johnson BK, Chu KC, Kranick RJ, Rayan M et al. Tumoroid model recreates clinically relevant phenotypes of high grade serous ovarian cancer (HGSC) cells, carcinoma associated fibroblasts, and macrophages. Acta Biomater. 2026;213:251\u201368.","DOI":"10.1016\/j.actbio.2026.02.005"},{"issue":"11","key":"3739_CR36","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1016\/j.celrep.2019.02.032","volume":"26","author":"I Chefetz","year":"2019","unstructured":"Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R, et al. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep. 2019;26(11):3061\u201375. e6.","journal-title":"Cell Rep"},{"issue":"12","key":"3739_CR37","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.7150\/thno.72037","volume":"12","author":"JH Kim","year":"2022","unstructured":"Kim JH, Park SY, Jeon SE, Choi JH, Lee CJ, Jang TY, et al. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5\/COX2 axis. Theranostics. 2022;12(12):5258\u201371.","journal-title":"Theranostics"},{"issue":"1","key":"3739_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41419-025-07916-2","volume":"16","author":"J Yao","year":"2025","unstructured":"Yao J, Huang X, Sun Q, Zhao W, Weygant N, Fan X, et al. Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma. Cell Death Dis. 2025;16(1):594.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3739_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13058-023-01642-3","volume":"25","author":"H Liu","year":"2023","unstructured":"Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6\/STAT3 signaling. Breast Cancer Res. 2023;25(1):43.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"3739_CR40","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1541-7786.MCR-17-0287","volume":"15","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, O\u2019Connell MR, Okugawa Y, Lee BS, Toiyama Y, Kusunoki M, et al. FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer. Mol Cancer Res. 2017;15(12):1678\u201391.","journal-title":"Mol Cancer Res"},{"key":"3739_CR41","doi-asserted-by":"publisher","first-page":"14983","DOI":"10.1038\/srep14983","volume":"5","author":"MR O\u2019Connell","year":"2015","unstructured":"O\u2019Connell MR, Sarkar S, Luthra GK, Okugawa Y, Toiyama Y, Gajjar AH, et al. Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications. Sci Rep. 2015;5:14983.","journal-title":"Sci Rep"},{"issue":"5","key":"3739_CR42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41374-021-00533-5","volume":"101","author":"T Guo","year":"2021","unstructured":"Guo T, Gu C, Li B, Xu C. PLODs are overexpressed in ovarian cancer and are associated with gap junctions via connexin 43. Lab Invest. 2021;101(5):564\u20139.","journal-title":"Lab Invest"},{"issue":"9","key":"3739_CR43","first-page":"2493","volume":"19","author":"L Gong","year":"2018","unstructured":"Gong L, Zheng Y, Liu S, Peng Z. Fibronectin Regulates the Dynamic Formation of Ovarian Cancer Multicellular Aggregates and the Expression of Integrin Receptors. Asian Pac J Cancer Prev. 2018;19(9):2493\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"3739_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10585-005-1262-y","volume":"22","author":"N Ahmed","year":"2005","unstructured":"Ahmed N, Riley C, Rice G, Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005;22(5):391\u2013402.","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"3739_CR45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1158\/1541-7786.MCR-13-0489","volume":"12","author":"A Usui","year":"2014","unstructured":"Usui A, Ko SY, Barengo N, Naora H. P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions. Mol Cancer Res. 2014;12(4):504\u201313.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"3739_CR46","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1172\/JCI33775","volume":"118","author":"HA Kenny","year":"2008","unstructured":"Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118(4):1367\u201379.","journal-title":"J Clin Invest"},{"issue":"6","key":"3739_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12032-024-02328-2","volume":"41","author":"QY Guo","year":"2024","unstructured":"Guo QY, Song JN, Chen YM, Yuan HN, Xue WS, Sun Y, et al. IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3\/HIF-1alpha pathway. Med Oncol. 2024;41(6):155.","journal-title":"Med Oncol"},{"key":"3739_CR48","doi-asserted-by":"publisher","first-page":"8334881","DOI":"10.1155\/2023\/8334881","volume":"2023","author":"T Zhang","year":"2023","unstructured":"Zhang T, Yang J, Sun Y, Song J, Gao D, Huang S, et al. Interleukin-6 and Hypoxia Synergistically Promote EMT-Mediated Invasion in Epithelial Ovarian Cancer via the IL-6\/STAT3\/HIF-1alpha Feedback Loop. Anal Cell Pathol (Amst). 2023;2023:8334881.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"9","key":"3739_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41389-021-00349-4","volume":"10","author":"N Niu","year":"2021","unstructured":"Niu N, Yao J, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis. 2021;10(9):65.","journal-title":"Oncogenesis"},{"issue":"25","key":"3739_CR50","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.1074\/jbc.M800109200","volume":"283","author":"LY Bourguignon","year":"2008","unstructured":"Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283(25):17635\u201351.","journal-title":"J Biol Chem"},{"key":"3739_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/1471-2407-14-317","volume":"14","author":"K Abubaker","year":"2014","unstructured":"Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, et al. Inhibition of the JAK2\/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014;14:317.","journal-title":"BMC Cancer"},{"issue":"1","key":"3739_CR52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12967-024-05205-8","volume":"22","author":"N Dadgar","year":"2024","unstructured":"Dadgar N, Sherry C, Zimmerman J, Park H, Lewis C, Donnenberg A, et al. Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis. J Transl Med. 2024;22(1):402.","journal-title":"J Transl Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03739-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03739-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03739-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:13:12Z","timestamp":1785107592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03739-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3739"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03739-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments involving human samples and animals were conducted in accordance with institutional and national guidelines. Human specimens were obtained under a protocol approved by the Institutional Review Board (IRB) of the University of Oklahoma Health Campus (IRB# 15066), and informed consent was obtained from all participants. The use of the human specimens for this study was approved under IRB #15587. All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Oklahoma Health Sciences Center (IACUC# 25-029-SCHI) and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. The maximal tumor burden permitted under the approved protocol was 2000\u00a0mm\u00b3. Tumor growth was monitored regularly, and this predefined maximal tumor size was not exceeded in any experimental animal. Humane endpoints were applied in all cases in accordance with approved guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CWH is the co-founder of COARE Holdings, Inc. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"166"}}